{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:39:44Z","timestamp":1789011584441,"version":"build-2803163510"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Sinusoidal Obstruction Syndrome (SOS) is a life threatening HSCT complication and it can rapidly evolve in Multiple Organ Dysfunction Syndrome, with a mortality exceeding 80%. Early treatment with defibrotide is the leading factor for efficacy. Its prophylactic use is recommended in the pediatric setting, but its value isn\u2019t validated for adults, although factors for individual risk assessment are debated. We here present a real-world experience of Defibrotide prophylaxis in adults at very high risk of SOS. We treated with prophylactic Defibrotide and Ursodeoxycholic Acid seven patients receiving allogeneic HSCT for high risk B-ALL, previously treated with single agent Inotuzomab-Ozogamicin. They all had other high risk factors for SOS such as previous hepatotoxicity, previous allo-HSCT, double alkylating conditioning. All patients received Treosulfan-Fludarabine conditioning, Thiotepa was added in 4 patients and 4GyTBI in 2 patients. GvHD prophylaxis included post-transplant cyclophosphamide, rapamycin and mycophenolate. Donor source was PBSC. Five patients received family MMRD transplant, 1 patient a MRD transplant and 1 patient a MUD transplant. Non-severe gastrointestinal bleeding occurred in two patients requiring defibrotide\u00a0temporarily discontinuation. SOS occurred in 3\/7 cases within 21 days after HSCT and no late-onset SOS were diagnosed. SOS caused death in all cases. All three patients were characterized by a common pattern of very high risk factors by prior HSCT, they all received a myeloablative conditioning with Treosulfan-Thiotepa and a MMRD transplant. Defibrotide prophylaxis apparently failed to protect against the development of SOS in those patients treated with a double alkylator-based conditioning regimen, while a possible efficacy for the other high-risk patients is debatable.<\/jats:p>","DOI":"10.3389\/fonc.2022.933317","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T01:36:35Z","timestamp":1655256995000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Fabio","family":"Giglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Lazzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Teresa","family":"Clerici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Lorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mastaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Marktel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Lupo-Stanghellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Marcatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Consuelo","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Piemontese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Peccatori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003569","article-title":"Veno-Occlusive Disease in HSCT Patients: Consensus-Based Recommendations for Risk Assessment, Diagnosis, and Management by the GITMO Group","volume":"105","author":"Bonifazi","year":"2021","journal-title":"Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.130","article-title":"Revised Diagnosis and Severity Criteria for Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease in Adult Patients: A New Classification From the European Society for Blood and Marrow Transplantation","volume":"51","author":"Mohty","year":"2016","journal-title":"Bone Marrow Transpl"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic Adverse Event Profile of Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia: Results From the Open-Label, Randomised, Phase 3 INO-VATE Study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30222","article-title":"Liver Complications Following Treatment of Hematologic Malignancy With Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin)","volume":"69","author":"McDonald","year":"2019","journal-title":"Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0939","article-title":"Liver Microvascular Injury and Thrombocytopenia of Antibody-Calicheamicin Conjugates in Cynomolgus Monkeys-Mechanism and Monitoring","volume":"23","author":"Guffroy","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01265-2","article-title":"A Multicentre, Multinational, Prospective, Observational Registry Study of Defibrotide in Patients Diagnosed With Veno-Occlusive Disease\/Sinusoidal Obstruction Syndrome After Haematopoietic Cell Transplantation: An EBMT Study","volume":"56","author":"Mohty","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.07.001","article-title":"Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease: Final Results From the International Compassionate-Use Program","volume":"22","author":"Corbacioglu","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12558","article-title":"BCSH\/BSBMT Guideline: Diagnosis and Management of Veno-Occlusive Disease (Sinusoidal Obstruction Syndrome) Following Haematopoietic Stem Cell Transplantation","volume":"163","author":"Dignan","year":"2013","journal-title":"Br J Haematol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"CD009311","DOI":"10.1002\/14651858.CD009311.pub2","article-title":"Interventions for Prophylaxis of Hepatic Veno-Occlusive Disease in People Undergoing Haematopoietic Stem Cell Transplantation","author":"Cheuk","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Paediatric Haemopoietic Stem-Cell Transplantation: An Open-Label, Phase 3, Randomised Controlled Trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-017-0019-y","article-title":"Management of Important Adverse Events Associated With Inotuzumab Ozogamicin: Expert Panel Review","volume":"53","author":"Kebriaei","year":"2018","journal-title":"Bone Marrow Transpl"},{"key":"B12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.04.020","article-title":"Outcomes of Allogeneic Stem Cell Transplantation After Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"25","author":"Marks","year":"2019","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.933317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T01:36:37Z","timestamp":1655256997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.933317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":13,"alternative-id":["10.3389\/fonc.2022.933317"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.933317","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"933317"}}